Relapsed follicular lymphoma

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) RECOMMEND idelalisib (ZYDELIG®) monotherapy as an option for appropriate patients with relapsed/refractory lymphoma.1*

View efficacy

*Please see the complete version of the NCCN Guidelines® for B-cell Lymphomas (V.4.2020) available on NCCN.org for specific recommendations.

Relapsed CLL

Updated results from final analysis of the pivotal trial 

View efficacy

 

ZYDELIG safety profile

Safety profile informed by multiple clinical studies

View details

ZYDELIG® AccessConnect®

Nurse support and financial assistance for ZYDELIG patients

Learn more

ZYDELIG is a PI3Kδ inhibitor indicated for

FL
Relapsed follicular lymphoma (FL) in patients who have received at least two prior systemic therapies.
CLL
Relapsed chronic lymphocytic leukemia (CLL) in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.
SLL
Relapsed small lymphocytic lymphoma (SLL) in patients who have received at least two prior systemic therapies.

FL and SLL are approved based on overall response rate. Improvement in patient survival or disease-related symptoms has not been established. Continued approval for these indications may be contingent upon verification of clinical benefit in confirmatory trials.

ZYDELIG is not indicated or recommended for first-line treatment of any patient or in combination with bendamustine and/or rituximab for the treatment of FL.

PI3K=phosphatidylinositol 3-kinase.

References:

  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-cell Lymphomas V.4.2020. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed August 25, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  2. ZYDELIG® (idelalisib) [Prescribing Information]. Foster City, CA: Gilead Sciences, Inc.; rev October 2020.